Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma.

abstract：OBJECTIVE:Prostate cancer is a leading cause of cancer death in men in the US. Castration-resistant prostate cancer (CRPC) is an advanced form of the disease and has a poor prognosis and limited treatment options. The objective of this study was to identify patients with CRPC from a medical claims database, and determi...

journal_title：Journal of medical economics

authors： Alemayehu B,Buysman E,Parry D,Becker L,Nathan F

更新日期：2010-01-01 00:00:00

abstract：:Aims: Allopurinol is the most common urate lowering therapy (ULT) used to treat gout but may cause life-threatening severe cutaneous adverse reactions (SCAR) in a small number of patients. Risk of SCAR is increased for patients with the HLA-B*58:01 genotype. When alternative ULT is required, febuxostat or probenecid a...

journal_title：Journal of medical economics

authors： Pruis SL,Jeon YK,Pearce F,Thong BY,Aziz MIA

更新日期：2020-08-01 00:00:00

abstract：OBJECTIVE:To compare 1-year costs and benefits of dapagliflozin (DAPA), a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, with those of other treatments for type 2 diabetes (T2D), such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), sulfonylureas (SUs), thiazolidinediones (TZDs), and dipeptidyl peptidase-4 ...

journal_title：Journal of medical economics

authors： Chakravarty A,Rastogi M,Dhankhar P,Bell KF

更新日期：2018-05-01 00:00:00

abstract：AIMS:The prevalence of atrial fibrillation (AF) has increased over the past years due to aging of the population, and healthcare costs associated with AF reflect a significant financial burden. The aim of this study was to explore predictors for the real-world AF-related in-hospital costs in patients that recently init...

journal_title：Journal of medical economics

authors： Jacobs MS,van Leent MWJ,Tieleman RG,Jansman FGA,Cao Q,Postma MJ,van Hulst M

更新日期：2017-12-01 00:00:00

abstract：OBJECTIVE:Abdominal paracentesis is commonly performed for diagnostic, therapeutic, and palliative indications, but the use of ultrasound guidance for these procedures is relatively recent, variable, and not well documented. A retrospective database analysis of abdominal paracentesis procedures was performed to determi...

journal_title：Journal of medical economics

authors： Patel PA,Ernst FR,Gunnarsson CL

更新日期：2012-01-01 00:00:00

abstract：OBJECTIVE:To assess patient characteristics, treatment patterns, and healthcare resource utilization (HRU)/costs of individuals treated for neuroendocrine tumors (NETs) in the US. METHODS:Using a US administrative claims database, this study identified commercially-insured adults newly diagnosed with carcinoid tumors ...

journal_title：Journal of medical economics

authors： Chuang CC,Bhurke S,Chen SY,Brulais S,Gabriel S

更新日期：2015-02-01 00:00:00

abstract：AIM:Prescription drug prices in the United States are considered rather extreme. Americans spend over $460 billion on drugs annually, or almost 17 percent of total national healthcare spending. How innovation incentives and insurance coverage drive pricing, diffusion, and utilization of drugs, under conditions of risk ...

journal_title：Journal of medical economics

authors： Mendoza RL

更新日期：2020-09-01 00:00:00

abstract：OBJECTIVE:To compare rates of severe relapse and total direct and indirect costs over a 2-year period between US-based employees with multiple sclerosis (MS) who were adherent and non-adherent to disease-modifying drugs (DMDs). METHODS:Employees with ≥1 MS diagnosis (ICD-9-CM: 340.x) and ≥1 DMD pharmacy claim between ...

journal_title：Journal of medical economics

authors： Ivanova JI,Bergman RE,Birnbaum HG,Phillips AL,Stewart M,Meletiche DM

更新日期：2012-01-01 00:00:00

abstract：OBJECTIVE:Basal insulin analogs are well established in the treatment of type 1 diabetes in Germany. However, little is known about their economic impact. The aim of this study for an adult population was to compare, from the perspective of the Statutory Health Insurance (SHI), the cost effectiveness of the long-acting...

journal_title：Journal of medical economics

authors： Pfohl M,Schädlich PK,Dippel FW,Koltermann KC

更新日期：2012-01-01 00:00:00

abstract：OBJECTIVES:Atazanavir (ATV) and darunavir (DRV) are protease inhibitors approved for HIV treatment in combination with ritonavir (/r). The objectives of this study were to compare persistence (time to treatment discontinuation/modification), adherence, and healthcare costs among patients with human immunodeficiency vir...

journal_title：Journal of medical economics

authors： Farr AM,Johnston SS,Ritchings C,Brouillette M,Rosenblatt L

更新日期：2016-01-01 00:00:00

abstract：OBJECTIVE:To estimate the cost-effectiveness of ipilimumab (3 mg/kg) compared with best supportive care (BSC) in pre-treated advanced melanoma patients. METHODS:The analysis was based on a US payer perspective and lifetime time horizon. A three-state Markov model was developed representing clinical outcomes, quality-o...

journal_title：Journal of medical economics

authors： Barzey V,Atkins MB,Garrison LP,Asukai Y,Kotapati S,Penrod JR

更新日期：2013-01-01 00:00:00

abstract：AIMS:Patients with psoriasis often undergo treatment with a sequence of biologic agents because of poor/loss of response to initial therapy. With the availability of newer agents like ixekizumab and secukinumab, there is a need for cost-effectiveness analyses to better reflect current clinical practice. This study aime...

journal_title：Journal of medical economics

authors： Johansson EC,Hartz S,Kiri SH,Kumar G,Svedbom A

更新日期：2018-08-01 00:00:00

abstract：:Objectives: Aging populations are contributing to an increased volume of osteoporotic fractures. The goals of this study were to (1) develop a scorecard on epidemiological burden, policy framework, service provision, and service uptake for osteoporosis in Saudi Arabia and (2) estimate the direct costs of managing oste...

journal_title：Journal of medical economics

authors： Aziziyeh R,Garcia Perlaza J,Saleem N,Sadat-Ali M,Elsalmawy A,McTavish RK,Duperrouzel C,Cameron C

更新日期：2020-07-01 00:00:00

abstract：:Aims: Cumulative exogenous factor VIII (FVIII) exposure is an important predictor of developing neutralizing antibodies (inhibitors) to FVIII in patients with persons with hemophilia A (PwHA). The aim of this study was to model the costs of emicizumab versus FVIII prophylaxis and total treatment costs for patients wit...

journal_title：Journal of medical economics

authors： Patel AM,Corman SL,Chaplin S,Raimundo K,Sidonio RF

更新日期：2019-12-01 00:00:00

abstract：:Background: Procedural efficiencies can contribute to cost reductions in transcatheter aortic valve replacement procedures (TAVR). The objective of this study is to determine operating room (OR) variable cost per minute in endovascular TAVR procedures, in a real-world hospital setting. Methods: Using Premier data from...

journal_title：Journal of medical economics

authors： Potter BJ,Ann Thompson C

更新日期：2019-10-01 00:00:00

abstract：OBJECTIVE:The objective of this study was to describe the economic burden to managed care associated with failure of selective serotonin reuptake inhibitor (SSRI) therapy in terms of direct medical costs. METHODS:A retrospective analysis of the PharMetrics database, a national managed care medical and pharmacy claims ...

journal_title：Journal of medical economics

authors： Balkrishnan R,Joish VN,Yang T,Jayawant SS,Mullins CD

更新日期：2008-01-01 00:00:00

abstract：INTRODUCTION:The patient cost burden of oral anticancer medicines has been associated with prescription abandonment, delayed treatment initiation, and poorer health outcomes in the US. Since 2011, several small molecule tyrosine kinase inhibitors have been approved for the treatment of non-small cell lung cancer (NSCLC...

journal_title：Journal of medical economics

authors： Seetasith A,Wong W,Tse J,Burudpakdee C

更新日期：2019-05-01 00:00:00

abstract：OBJECTIVE:The objective of this study was to analyse hospital incidence of osteogenesis imperfecta (OI) in Spanish hospitals and the associated medical costs from a healthcare system perspective. METHODS:To this aim, a retrospective multicentre study was designed analysing admission records from patients admitted with...

journal_title：Journal of medical economics

authors： Darbà J,Marsà A

更新日期：2020-10-21 00:00:00

abstract：BACKGROUND:Non-vitamin K antagonist oral anticoagulants (NOACs) have been included in international guidelines as important alternatives to vitamin K antagonists (VKAs) for the treatment of venous thromboembolism (VTE) and stroke prevention in non-valvular atrial fibrillation (NVAF). Meanwhile, in the Netherlands, NOAC...

journal_title：Journal of medical economics

authors： de Jong LA,Gout-Zwart JJ,van den Bosch M,Koops M,Postma MJ

更新日期：2019-04-01 00:00:00

abstract：OBJECTIVES:To assess the cost effectiveness of palivizumab, a humanised monoclonal antibody, used as prevention against severe respiratory syncytial virus (RSV) infection requiring hospitalisation, in infants with haemodynamically significant congenital heart disease (CHD) in the German healthcare setting. STUDY DESIG...

journal_title：Journal of medical economics

authors： Nuijten M,Lebmeier M,Wittenberg W

更新日期：2009-01-01 00:00:00

abstract：INTRODUCTION:Myelofibrosis is a non-frequent chronic myeloproliferative Philadelphia-negative chromosome neoplasm. It is a heavy incapacitating orphan disease and associated with high morbidity and mortality. In this context, indirect and non-medical costs are expected to be high. The main objective of this project is ...

journal_title：Journal of medical economics

authors： Gimenez E,Besses C,Boque C,Velez P,Kerguelen A,Cervantes F,Ferrer-Marin F,Perez-Encinas M,Rodriguez M,Gonzalez JD,Calzada R,Hernandez-Boluda JC

更新日期：2014-06-01 00:00:00

abstract：:Aims: To assess healthcare resource utilization (HCRU) and costs in patients with non-small cell lung cancer treated with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors afatinib or erlotinib as first-line treatment.Materials and methods: This retrospective analysis used data from three large ad...

journal_title：Journal of medical economics

authors： Samuelsen C,Lim J,Golembesky A,Shrestha S,Wang L,Griebsch I

更新日期：2020-01-01 00:00:00

abstract：OBJECTIVE:Two human papillomavirus (HPV) vaccines are on the market. Based on expected differences in sustained- and cross-protection between the two vaccines, their long-term economic value is modelled and compared for France, Ireland and Italy. METHODS:A Markov cohort model reproducing the natural history of HPV inf...

journal_title：Journal of medical economics

authors： Demarteau N,Standaert B

更新日期：2010-01-01 00:00:00

abstract：BACKGROUND:Currently the majority of cancer deaths occur in low- and middle-income countries, where there are appreciable funding concerns. In Kenya, most patients currently pay out of pocket for treatment, and those who are insured are generally not covered for the full costs of treatment. This places a considerable b...

journal_title：Journal of medical economics

authors： Atieno OM,Opanga S,Martin A,Kurdi A,Godman B

更新日期：2018-09-01 00:00:00

abstract：OBJECTIVE:To evaluate the cost-effectiveness of biphasic insulin lispro mix 75/25 (LM75/25) and mix 50/50 (LM50/50) compared with a long-acting analog insulin (LAAI) regimen from the perspective of a US healthcare payer. METHODS:A published computer simulation model of diabetes was used to evaluate the cost-effectiven...

journal_title：Journal of medical economics

authors： Pollock RF,Curtis BH,Valentine WJ

更新日期：2012-01-01 00:00:00

abstract：AIMS:Hormonal imbalances can affect a woman's physical and mental condition, impacting her daily life and productivity. A mobile application, "Karada-no-kimochi", predicts the menstrual cycle based on recorded data, and provides the information regarding menstruation. This study investigates the effectiveness of the ap...

journal_title：Journal of medical economics

authors： Song M,Kanaoka H

更新日期：2018-11-01 00:00:00

abstract：OBJECTIVE:The economic implications from the US Medicare perspective of adopting alternative treatment strategies for acute bacterial skin and skin structure infections (ABSSSIs) are substantial. The objective of this study is to describe a modeling framework that explores the impact of decisions related to both the lo...

journal_title：Journal of medical economics

authors： Revankar N,Ward AJ,Pelligra CG,Kongnakorn T,Fan W,LaPensee KT

更新日期：2014-10-01 00:00:00

abstract：BACKGROUND:Systemic Candida infections (SCI) occur predominantly in intensive care unit patients and are a common cause of morbidity and mortality. Recently, changes in Candida epidemiology with an increasing prevalence of SCI caused by Candida non-albicans species have been reported. Resistance to fluconazole and azol...

journal_title：Journal of medical economics

authors： Masterton RG,Casamayor M,Musingarimi P,van Engen A,Zinck R,Odufowora-Sita O,Odeyemi IA

更新日期：2013-11-01 00:00:00

abstract：BACKGROUND:Neuroblastoma (NB) is notorious in childhood cancer because of its high incidence and poor prognosis. The Children's Oncology Group reported that the 3-year OS in the high-risk (HR) group is 50%, and the HR-NB with bone marrow metastasis in our center is 43.1%. Thousands of families in China suffer from the ...

journal_title：Journal of medical economics

authors： Jiang C,Cai S,Duan C,Xu N,Zhou Y,Peng X,Ma X

更新日期：2020-09-01 00:00:00

abstract：OBJECTIVE:The past few decades have been marked by a bold increase in national health spending across the globe. Rather successful health reforms in leading emerging markets such as BRICS reveal a reshaping of their medical care-related expenditures. There is a scarcity of evidence explaining differences in long-term m...

journal_title：Journal of medical economics

authors： Jakovljevic MM

更新日期：2016-01-01 00:00:00